Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.

CONCLUSIONS: Both imatinib dose escalation and sunitinib were optional in Asian patients after failure of first-line imatinib, and patients with KIT exon 11 mutation benefited more from a direct shift to sunitinib. PMID: 30346846 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30346846?dopt=Abstract

Source: Scandinavian Journal of Gastroenterology - October 24, 2018 Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research